Mersana Therapeutics Inc (MRSN)
1.91
+0.07
(+3.80%)
USD |
NASDAQ |
Nov 05, 10:19
Mersana Therapeutics Debt to Equity Ratio: 3.012 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2024 | 3.012 |
| March 31, 2024 | 0.9043 |
| December 31, 2023 | 0.6837 |
| September 30, 2023 | 0.4819 |
| June 30, 2023 | 0.2793 |
| March 31, 2023 | 0.3889 |
| December 31, 2022 | 0.2708 |
| September 30, 2022 | 0.2754 |
| June 30, 2022 | 0.1849 |
| March 31, 2022 | 0.1758 |
| December 31, 2021 | 0.2023 |
| September 30, 2021 | 0.0326 |
| June 30, 2021 | 0.0258 |
| March 31, 2021 | 0.0253 |
| December 31, 2020 | 0.0218 |
| September 30, 2020 | 0.0195 |
| Date | Value |
|---|---|
| June 30, 2020 | 0.018 |
| March 31, 2020 | 0.0776 |
| December 31, 2019 | 0.0622 |
| September 30, 2019 | 0.052 |
| June 30, 2019 | 0.0443 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
0.018
Minimum
Jun 2020
3.012
Maximum
Jun 2024
0.3759
Average
0.1849
Median
Jun 2022
Debt to Equity Ratio Benchmarks
| Chimerix Inc | 0.00 |
| Cellectar Biosciences Inc | -- |
| Marinus Pharmaceuticals Inc | -1.196 |
| Jaguar Health Inc | 1.948 |
| Seres Therapeutics Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 179.13M |
| Total Liabilities (Quarterly) | 170.70M |
| Shareholders Equity (Quarterly) | 8.427M |
| Current Ratio | 2.717 |
| Net Debt Paydown Yield | -0.03% |